These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 30862686

  • 1. Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.
    Lee SC, Shestov AA, Guo L, Zhang Q, Roman JC, Liu X, Wang HY, Pickup S, Nath K, Lu P, Hofbauer S, Mesaros C, Wang YL, Nelson DS, Schuster SJ, Blair IA, Glickson JD, Wasik MA.
    Mol Cancer Res; 2019 Jun; 17(6):1365-1377. PubMed ID: 30862686
    [Abstract] [Full Text] [Related]

  • 2. Impact of therapeutic inhibition of oncogenic cell signaling tyrosine kinase on cell metabolism: in vivo-detectable metabolic biomarkers of inhibition.
    Nath K, Gupta PK, Basappa J, Wang S, Sen N, Lobello C, Tomar JS, Shestov AA, Orlovskiy S, Arias-Mendoza F, Rauert-Wunderlich H, Nelson DS, Glickson JD, Wasik MA.
    J Transl Med; 2024 Jul 04; 22(1):622. PubMed ID: 38965536
    [Abstract] [Full Text] [Related]

  • 3. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
    Li CJ, Jiang C, Liu Y, Bell T, Ma W, Ye Y, Huang S, Guo H, Zhang H, Wang L, Wang J, Nomie K, Zhang L, Wang M.
    Mol Cancer Ther; 2019 Feb 04; 18(2):267-277. PubMed ID: 30413649
    [Abstract] [Full Text] [Related]

  • 4. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
    Zhang Q, Wang HY, Liu X, Nunez-Cruz S, Jillab M, Melnikov O, Nath K, Glickson J, Wasik MA.
    J Immunol; 2019 Oct 15; 203(8):2043-2048. PubMed ID: 31534006
    [Abstract] [Full Text] [Related]

  • 5. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
    Wang X, Fei Y, Liu X, Zhang T, Li W, Jia X, Liu X, Qiu L, Qian Z, Zhou S, Ren X, Zhai Q, Meng B, Li L, Zhang H.
    Aging (Albany NY); 2021 Sep 10; 13(17):21102-21121. PubMed ID: 34508613
    [Abstract] [Full Text] [Related]

  • 6. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S, Johnson A, Chang B, Ely S, Elemento O, Mason CE, Leonard JP, Chen-Kiang S.
    Cancer Discov; 2014 Sep 10; 4(9):1022-35. PubMed ID: 25082755
    [Abstract] [Full Text] [Related]

  • 7. Ibrutinib for mantle cell lymphoma.
    Tucker DL, Rule SA.
    Future Oncol; 2016 Feb 10; 12(4):477-91. PubMed ID: 26759179
    [Abstract] [Full Text] [Related]

  • 8. Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
    Ran F, Liu Y, Chen X, Zhuo H, Xu C, Li Y, Duan X, Zhao G.
    Bioorg Chem; 2021 Jul 10; 112():104968. PubMed ID: 34000704
    [Abstract] [Full Text] [Related]

  • 9. The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.
    Lantermans HC, Ma F, Kuil A, van Kesteren S, Yasinoglu S, Yang G, Buhrlage SJ, Wang J, Gray NS, Kersten MJ, Treon SP, Pals ST, Spaargaren M.
    Leukemia; 2024 Jul 10; 38(7):1570-1580. PubMed ID: 38454120
    [Abstract] [Full Text] [Related]

  • 10. Emerging Role of Functional Magnetic Resonance Spectroscopy (MRS) to Monitor Response to Kinase Inhibitors in Cancer.
    Nath K, Gupta PK, Wasik MA.
    Adv Cancer Res Clin Imaging; 2024 Jul 10; 4(3):. PubMed ID: 39161974
    [Abstract] [Full Text] [Related]

  • 11. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
    Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML.
    Ann Oncol; 2015 Jun 10; 26(6):1175-1179. PubMed ID: 25712454
    [Abstract] [Full Text] [Related]

  • 12. Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.
    Ahmed M, Lorence E, Wang J, Jung D, Zhang L, Nomie K, Wang M.
    Sci Signal; 2019 Feb 05; 12(567):. PubMed ID: 30723172
    [Abstract] [Full Text] [Related]

  • 13. Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.
    Ran F, Liu Y, Yu S, Guo K, Tang W, Chen X, Zhao G.
    Bioorg Chem; 2020 Jan 05; 94():103367. PubMed ID: 31685258
    [Abstract] [Full Text] [Related]

  • 14. Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.
    De SK.
    Curr Med Chem; 2024 Jan 05; 31(30):4757-4762. PubMed ID: 37818564
    [Abstract] [Full Text] [Related]

  • 15. Targeting protein kinase C in mantle cell lymphoma.
    Rauert-Wunderlich H, Rudelius M, Ott G, Rosenwald A.
    Br J Haematol; 2016 May 05; 173(3):394-403. PubMed ID: 26914495
    [Abstract] [Full Text] [Related]

  • 16. MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
    Wu X, Nowakowski KE, Abeykoon JP, Manske M, Stenson MJ, Timm MM, Hanson CA, Van Dyke DL, Dasari S, Witzig TE.
    Eur J Haematol; 2021 Oct 05; 107(4):458-465. PubMed ID: 34214199
    [Abstract] [Full Text] [Related]

  • 17. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
    Jiang VC, Liu Y, Lian J, Huang S, Jordan A, Cai Q, Lin R, Yan F, McIntosh J, Li Y, Che Y, Chen Z, Vargas J, Badillo M, Bigcal JN, Lee HH, Wang W, Yao Y, Nie L, Flowers CR, Wang M.
    J Clin Invest; 2023 Feb 01; 133(3):. PubMed ID: 36719376
    [Abstract] [Full Text] [Related]

  • 18. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
    Thieme E, Liu T, Bruss N, Roleder C, Lam V, Wang X, Nechiporuk T, Shouse G, Danilova OV, Bottomly D, McWeeney SK, Tyner JW, Kurtz SE, Danilov AV.
    Cell Death Dis; 2022 Mar 16; 13(3):246. PubMed ID: 35296646
    [Abstract] [Full Text] [Related]

  • 19. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
    Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S.
    Leuk Res; 2013 Oct 16; 37(10):1271-7. PubMed ID: 23962569
    [Abstract] [Full Text] [Related]

  • 20. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
    Jacobson C, Kopp N, Layer JV, Redd RA, Tschuri S, Haebe S, van Bodegom D, Bird L, Christie AL, Christodoulou A, Saur A, Tivey T, Zapf S, Bararia D, Zimber-Strobl U, Rodig SJ, Weigert O, Weinstock DM.
    Blood; 2016 Nov 24; 128(21):2517-2526. PubMed ID: 27742706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.